Founded in 1999, we are an international biotech company committed to our goal of improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, our passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function enhanced antibodies. By 2030, our vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines.
Genmab
Unlock to Claim this listing
Add / Modify Company
Click to rate this company
[Total: 0 Average: 0]
Click here to sign in to vote
3.8
Overall Excellence Rating
Industry
Pharmaceuticals & BiotechnologyCategory
Biotechnology ResearchESG/Ethical Impact
OUR PURPOSE: Combating cancer and other serious diseases through the power of antibodies. Our core purpose summarizes what we strive for – our unstoppable team will improve the lives of patients through innovative and differentiated antibody therapeutics. It supports our vision which captures our aspirations for our future – that by 2030, our knock-your-socks-off antibody medicines (KYSO antibody medicines®) are transforming the lives of people with cancer and other serious diseases.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer.
Awards Received
2023
Revenues
2392000000
Website Traffic
Employee Rating
4.4
Customer Rating
3.9
Company Size
1000-5000
ESG Risk Rating
3
We’re Happy to Help.
Do you have questions about your ranking, our projects, or why you’re not on the list?


